Opinion

Video

Payer Needs and Strategies for Evaluating and Covering PDTs

Panelists delve into the data and the cost-saving evidence required by payers to cover prescription digital therapeutics (PDTs), outline the decision-making process followed by payers, and share best practices observed in real-world to ensure the successful implementation of PDTs.

Related Videos
1 KOL is featured in this series.
1 expert is featured in this series.
5 experts are featured in this series
Related Content
Dr Yehuda Handelsman
December 20th 2024

Dr Yehuda Handelsman on How DCRM 2.0 Guidelines Refine CRM Disease Management

Brooke McCormick
In this interview, Yehuda Handelsman, MD, highlights key updates to the Diabetes, Cardiorenal, and Metabolic (DCRM) guidelines in DCRM 2.0, shaped by global collaboration and recent clinical insights.
Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi
December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.
Top 5 Rare Blood
December 20th 2024

Top 5 Most-Read Articles on Rare Blood Disorders in 2024

Giuliana Grossi
Key findings from 2024 focused on conditions like vaccine-induced immune thrombotic thrombocytopenia, immune thrombocytopenia, and hemophilia, stressing the importance of early detection and innovative therapies.
Managed Care Cast
October 29th 2024

Breaking the Cycle: The Importance of Early Intervention in Hidradenitis Suppurativa

Giuliana Grossi
Prompt care supports mental well-being, as hidradenitis suppurativa is often associated with depression and anxiety due to its physical and social challenges.
Myasthenia gravis diagnosis | Image Credit: ©syahrir-stock.adobe.com
December 19th 2024

Further Refining the Myasthenia Gravis Continuum

Gayle Turim Dickstein
Finding similar frequencies of positive acetylcholine receptor antibodies in patients with ocular and generalized myasthenia gravis (MG), a Danish research team posits that ocular disease is most likely a more moderate form of generalized MG—not a fully separate condition.
CHEST 2024 highlights | Image Credit: Venngage
December 19th 2024

ICYMI: Highlights From CHEST 2024

Brooke McCormick
The top 5 most-viewed content from CHEST 2024 included expert interviews and coverage on multiple areas of chest medicine.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo